PROTACs in cancer immunotherapy: a minireview
Biochemical Society Transactions · 29.10.2025 · 53 (05) · 1273-1281
DOI: 10.1042/bst20253065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Society Transactions, online erschienen am 01.10.2025. Verfasst von Köckenberger J E und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, 92093, U.S.A. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Proteolysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The discovery of immune checkpoint blockade as a therapeutic strategy to induce immunogenic cancer cell elimination has shown great success in the treatment of various cancers. However, limited response rates highlight the need for further development in this field. Promising new preclinical developments include the discoveries of proteolysis-targeting chimeras (PROTACs) to interfere with tumor immune escape signaling. Pharmacological induction of targeted protein degradation by these chimeras has shown advantages in inhibiting non-enzymatic protein functions and difficult to target protein–protein interactions. Furthermore, the induced degradation was shown to promote changes in the major histocompatibility complex I ligandome, which can be leveraged for an immune stimulus, increasing the cancer immune response. In this minireview, we highlight the research efforts ongoing towards employing PROTACs in immunotherapy for cancer treatment. Specifically, we outline how the unique mechanism of action can be leveraged to enhance the immune response or inhibit immune suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, 92093, U.S.A.
- Moores Cancer Center, University of California San Diego Health, La Jolla, CA, 92037, U.S.A.
- Department of Pharmacology, University of California San Diego, School of Medicine, La Jolla, CA, 92093, U.S.A.
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, 92093, U.S.A.
ORCID-Profile: Köckenberger J E, Ferguson F M
Zitieren
APA
J E, K., E S, C. A., E T, C., J S, G., & F M, F. (2025). PROTACs in cancer immunotherapy: a minireview. Biochemical Society Transactions, 53(05), 1273-1281. https://doi.org/10.1042/bst20253065
Vancouver
J E K, E S CA, E T C, J S G, F M F. PROTACs in cancer immunotherapy: a minireview. Biochemical Society Transactions. 2025;53(05):1273-1281. doi:10.1042/bst20253065
BibTeX
@article{JE2025,
author = {J E, Köckenberger and E S, Cardenas Alcoser and E T, Chang and J S, Gutkind and F M, Ferguson},
title = {PROTACs in cancer immunotherapy: a minireview},
journal = {Biochemical Society Transactions},
year = {2025},
volume = {53},
number = {05},
pages = {1273--1281},
doi = {10.1042/bst20253065}
}
EUVIMED